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1 Picotamide has been shown to interfere competitively with the thromboxane A2
(TxA2) platelet receptor. In the present study the effect of in vivo administration of
picotamide on TxA2 human platelet receptors was investigated in 10 healthy subjects.
2 Picotamide (300 mg x 3 daily) or placebo were administered in a double-blind, cross-
over, placebo controlled study, each treatment lasting 1 week with a 2 week interval
period. TxA2 receptors were investigated by a direct radioligand binding assay method
employing [1251]-PTA-OH as labelled ligand. Platelet studies were performed on the
first day of treatment immediately before and 2, 4 and 8 h after the ingestion of the
drug. The effects of chronic administration were assessed on the seventh day.
3 Two and 4 h after the administration of picotamide 300 mg orally platelet TxA2
receptors were significantly reduced from 1366 ± 237 to 957 ± 221 (P < 0.05) and 753
+ 119 receptors/platelet (mean ± s.d.) (P < 0.03). After 8 h platelet receptor
population was restored (1362 ± 324, NS). The same pattern was observed after 7
days of treatment. Thus picotamide seems to induce a short lasting down regulation
of platelet TxA2 receptors.
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Introduction Methods
The exposure of cells to agonists often results in a short
or medium term decrease in responsiveness of the cells
to the agonist (Benovic et al., 1985; Harden, 1983),
frequently accompanied by a loss in the specific membrane
receptors for the agonist. This agonist-induced desensitiz-
ation has also been reported for platelets. In fact anti-
platelet drugs with specific agonist effects on PGI2 or
PGD2 receptors have been reported to induce down-
regulation of specific membrane platelet receptors either
after in vitro incubation (Alt et al., 1986; Jaschonek et
al., 1988) or in vivo administration (Modesti et al., 1987)
and this phenomenon limits the efficacy and the usefulness
of these drugs. This down-regulation pattern was also
observed to occur in vitro after platelet incubation with
a TxA2 analogue (Crouch & Lapetina, 1989; Liel et al.,
1988; Murray & FitzGerald, 1989). The reduction in
TxA2 receptor number in vivo after the administration
of TxA2 inhibitors might represent a useful additional
effect for drugs interacting with specific TxA2 receptors.
This study was undertaken to investigate whether the
administration of a drug with TxA2 receptor antagonist
activity (picotamide) to healthy subjects induced changes
in affinity and/or density of the TxA2 platelet receptors,
assessed by the binding of the labelled antagonist [125I]_
PTA-OH.
Materials
ONO11120 (9,11-dimethylmethano-11,12-methane-16-
phenyl-13,14-dihydro-13-aza-15-tetranor-TxA2) (Naru-
miya et al., 1986) was a kind gift ofDr Narumiya (Kyoto,
Japan). [125I]-PTA-OH (2000 Ci mmol-1) (9,11-dimethyl-
methano-11,12-methano-16-(3 [1231]-4-hydroxyphenyl)-
13,14-dihydro-13-aza-15-tetranor-TxA2), the labelled
hydroxylated form of ON011120, was obtained from
Amersham (Buckinghamshire, GB). Prostacycin (PGI2)
was obtained from Upjohn (Kalamazoo, Mi, USA). Pico-
tamide (N,N'bis(3-picolyl)-4-methoxy-isophthalamide)
(batch no 870311) was provided by the SAMIL inc.-
Sandoz Group, Rome, Italy. All the other reagents were
obtained from Merck (Darmstadt, F.R.G.) and were of
analytical grade.
Experimental procedure
Ten healthy subjects aged 44 to 62 years were treated
with placebo or picotamide (Plactidil, Samil-Sandoz,
Italy) 300 mg three times daily orally in a double-blind,
cross-over placebo controlled clinical study. The two
treatments, each lasting 1 week, were separated by a 1
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week wash-out interval. No subject had taken any other
drug for at least 15 days preceding the study. Blood
samples for binding studies were collected on the first
and on the last day of each treatment period before the
first administration (08.00 h) of picotamide or placebo
respectively and 2, 4 and 8 h after picotamide or placebo
administration.
Blood sampling and platelet isolation
Blood was withdrawn by clean venepuncture and anti-
coagulated with 15% (v/v) acid citrate dextrose (NIH
formula A).
Platelet-rich plasma was prepared as previously des-
cribed (Neri Serneri et al., 1984). Platelet counts were
performed by an automatic counter (Platelet analyzer
810, Baker Instruments, Allentown, PA, USA). Platelet-
rich plasma, adjusted to pH 6.5 with acid citric dextrose,
was centrifuged at 1,800 g for 30 min at room temperature
(20-22° C). Platelets were then resuspended in 10 ml
of phosphate buffer pH 7.2 (8 mmol 1-1 Na2HPO4,
2 mmol 1-1 NaH2PO4, 10 mmol 171 KCI,
135 mmol 1-1 NaCl) and again recentrifuged at 1,800 g
for 30 min at room temperature. The supernatant was
discarded and the platelets were resuspended in assay
buffer containing 138 mmol 1-1 NaCl, 5 mmol I1 MgCl2,
1 mmol 1-1 EGTA and 25 mmol 1-1 Tris/HCl, pH 7.5.
If necessary assay buffer was added to obtain a platelet
concentration of 109 platelets ml-1.
Binding studies
Kinetics of 125I-PTA-OH binding The binding of 0.5
nmol I-' [1251]-PTA-OH (final concentration, f.c.) to
108 platelets at room temperature, in a final volume of
0.2 ml was preliminarily evaluated at selected time
intervals Non-specific binding was assessed at each time
by adding 0.02 ml of ONO11120 (2 x 10-5 mol l-1, f.c.).
Specific binding at each time was then calculated as the
difference between total and non-specific platelet bound
radioactivity. After 10 min the reversibility of the binding
was assessed by adding a large amount of unlabelled
ligand (0.02 ml of ON011120, 2 x 10-5 mol l-1, f.c.)
to the reaction mixture and the residual binding was
evaluated at selected time intervals.
[1251]-PTA-OH binding isotherms Platelet suspension
(0.1 ml) was incubated in a final volume of 0.2 ml with
[1251]-PTA-OH 0.05 nmol 1-1 (f.c.) (2000 Ci mmol-1),
plus ON011120 at increasing selected concentrations
(0 to 4 x 10-6 mol 1-1) for 10 min at room temperature.
The residual radioactivity after the addition of ON011120
2 x 10- mol F1 (f.c.) was considered as non-specific
binding. Non-specific binding of 0.05 nmol 1-1
[1251]-PTA-OH amounted to 25-35% of total bound
radioactivity.
After 10 min incubation four 4 ml aliquots of ice-cold
buffer were added to each tube to stop the reaction and
the contents were rapidly filtered under reduced pressure
through Whatman GF/C glass microfiber filters. Previous
time course experiments showed that under these
conditions binding equilibrium had been reached. The
entire washing procedure was completed within about
15 s. Filters were dried under air flow and counted in a
Beckman gamma counter with an overall efficiency of
50%. The experiments were carried out in triplicate.
Analysis of data
Kinetic studies The kinetic constants were calculated
by time course experiments according to Weiland &
Molinoff (1981). Briefly, the observed association
constant (K0b) was calculated as the slope of the pseudo-
first order plot:
ln(LReq)/((LReq) - (LRt)) vs time (t).
LReq and LRt respectively indicate the concentration
of ligand-receptor complex at equilibrium and at each
time (t).
The dissociation rate constant K,1 is a first order rate
constant because the rate is determined after elimination
of the forward reaction following prior incubation of
ligand and receptor. The first order integrated rate
equation for dissociation is:
ln(LRt)/(LR) = -K_1
LR and LRt are the concentrations of ligand-receptor
complex just prior to the addition of competing ligand
(time 0) and at time t respectively. The association
constant (K+,) was then calculated by the equation:
K+1 = (Kob-K-,)/[L]
The kinetically determined dissociation constant (Kd) is
finally given by:
Kd=K=,IK+l
Binding isotherms The total binding for each concentra-
tion in displacement curve at equilibrium was determined
by dividing the decay per minute (d min-') of each
platelet pellet by the calculated specific activity in
d min-' mol-1 (Modesti et al., 1985). The analysis of
these binding isotherms was performed according to
Scatchard (1949).
Hill Plot of the displacement curve and Ki were calcu-
lated according to Cheng & Prusoff (1973).
Statistical analysis
If not otherwise indicated, all data given in the text are
mean ± 1 s.d. of n experiments. The receptor numbers
and the dissociation constants at each time were compared
by analysis of variance.
Results
Time course and binding isotherms of the [125I]-PTA-
OH binding
[1251]-PTA-OH rapidly bound to intact human platelets
(Figure 1). The observed rate constant (KObS) for specific
binding was 0.340 min-' (the equation for the line was
y = - 0.026 + 0.340x; n = 5). The dissociation curve
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Figure 1 a) Time course of the association and dissociation
phase of the binding of [1251]-PTA-OH (0.5 nmol l-1) to
washed human platelets at room temperature. Dissociation
was obtained after 10 min incubation upon addition of 20,000
nmol 1-1 ON011120 to the incubation mixture. Data points
represent means of triplicate determinations in at least five
independent experiments. b) Specific binding association is
plotted according to the pseudo-first order rate equation (Kobs
= 0.340 min-'). c) Dissociation is plotted as a first order
reaction (K-1 = 0.324 min-1; K, = (Kobs - K-1) 1-1 = 0.032
nmol 1-1 min-'; Kd = K_,/K, = 10 nmol l-1).
performed after 10 min of incubation showed a rapid
displacement of about 65-75% of the total radioactivity
bound. The analysis of the first order rate of dissociation
showed a linear pattern with a K-1 of 0.324 min-1 (n = 5).
The association rate constant (K1) was 0.032 nmol 1-1
min-' and the resulting kinetically determined dissoci-
ation constant Kd was 10 nmol l-1.
The saturation of [1251]-PTA-OH binding occurred at
a ligand concentration about 100 nmol 1- (Figure 2).
The Scatchard analysis of this binding yielded a straight
line, indicating a single class of binding sites for [12 -
PTA-OH (Figure 2). The equilibrium dissociation
constant (Kd) and the maximum concentration of binding
sites (Bmax) determined by Scatchard analysis, gave values
of 21.5 ± 7.2 nmol 1[1 and 198 ± 63 fmol/108 platelets
(1194 ± 379 binding sites per platelet, n = 12) respectively.
Hill coefficient (n Hill) of the binding was 0.942 ± 0.099,
suggesting the existence of homogeneous individual class
of binding sites without cooperativity (Figure 3).
Effect of picotamide administration The number or
affinity of TxA2 receptors did not undergo any significant
changes after the administration of placebo. In contrast,
a significant reduction of platelet membrane receptors
was found 2 h (957 ± 221 receptors/platelet, P < 0.05)
and 4 h (753 ± 119 receptors/platelet, P < 0.03) after
picotamide administration in comparison with placebo
administration. After 8 h platelet receptor population
was completely restored (1362 ± 324 receptors/platelet,
NS) (Figure 4) (Table 6). No changes in the affinity for
the ligand were observed after picotamide.
The chronic administration of the drug for 1 week
did not induce a significant change in TxA2 platelet
receptors. In fact binding studies did not show any
significant differences in patients treated with picotamide
when compared with patients treated with placebo before
drug administration.
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Figure 2 Saturation curve of the [125I]-PTA-OH binding to
washed human platelets at room temperature. (O = total
binding; * = specific binding; = non specific binding) (n =
12). Inset: Scatchard analysis of the specific binding (Bmax =
198 ± 63 fmol/108 platelets, Kd = 21.5 ± 7.2 nmol 1-1).
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Figure 3 Hill plot of the displacement curve. Ki, calculated
according to Cheng & Prusoff (1973), was 19 ± 4 nmol 1-1 (n
= 10, n Hill = 0.942).
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Figure 4 Number ofTxA2 receptors per platelet after placebo
(@) or picotamide administration (U, 300 mg orally). *P <
0.05, **P < 0.01.
Discussion
Present results indicate that picotamide administration
to humans induces a reduction of the TxA2 binding
sites available on the platelet membrane. This effect
is reversible and is not observed 8 h after the last
administration.
The kinetics of platelet TxA2 receptor desensitization
observed in vivo and the kinetic studies of [125I]-PTA-OH
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Table 1 TxA2 receptor number and dissociation constant after
picotamide or placebo administration (mean ± s.d.)
Basal 2 h 4h 8h
Binding sites/platelet
Picotamide 1366 ± 237 957 ± 221* 753 ± 119** 1362 ± 324
Placebo 1291 ± 211 1360 ± 324 1294 ± 258 1312 ± 308
Dissociation constant (nmol 1-1)
Picotamide 19 ± 3.8 17 ± 5.7 23 ± 7.8 22 ± 4.2
Placebo 21 ± 4.1 19 ± 2.9 21 ± 6.2 18 ± 3.8
* = P < 0.05, **P = < 0.01
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Figure 5 To evaluate the occupancy of the thromboxane
platelet receptors by picotamide after platelet washing
according to the protocol used, separate samples of platelet
rich plasma (PRP) were incubated with ONO11120 (O, 1 ,umol
I'), picotamide (U 2 ,umol l-1) or buffer (*) at 370 C. Before
and after 5, 10 and 120 min of incubation, samples were washed
and binding sites for [1251]-PTA-OH were determined (see
Methods).
inhibition by picotamide seem to stand against the
possibility that the reduction of specific [1251]-PTA-OH
binding sites could be simply due to the incomplete
removal of the agonist with residual receptor occupation.
In fact during the platelet washing procedure performed
during binding studies, picotamide is easily removed
from its specific receptors due to its relatively high
dissociation constant (Modesti et al., 1989). Moreover
in vitro experiments confirmed that the TxA2 binding
capacity of platelets was unchanged after a short incuba-
tion with picotamide.
Desensitization of platelet thromboxane A2 receptors
by TxA2 analogues has been recently reported to occur
in vitro (Crouch & Lapetina, 1989; Liel et al., 1988;
Murray & Fitzgerald, 1989; Sato et al., 1989). In fact
platelets incubated with stable TxA2 analogues rapidly
(within few minutes) reach a desensitized state (Liel et
al., 1988; Murray & Fitzgerald, 1989). The sequence of
events in TxA2 receptor desensitization was found to
involve initial uncoupling of the receptor from a guanine
nucleotide binding (G) protein, followed by a receptor
down regulation with a loss of specific membrane binding
sites (Murray & Fitzgerald, 1989). In fact after an initial
rapid uncoupling of the TxA2 receptor and its associated
G protein, a slow down regulation of receptors was
observed. This pattern was observed to occur in vitro
after incubation either with an agonist (U46619) (Liel et
al., 1988) or an antagonist (ONO11120) (Murray &
Fitzgerald, 1989). The early desensitization after TxA2
analogue stimulation could be physiologically relevant
to the modulation of the platelet response to endogenous
TxA2. In fact TxA2 potentiates platelet aggregation
induced by other platelet stimulants (ADP, adrenaline)
and is released by platelets in response to different
stimuli or pathophysiological conditions, so that this
desensitization could represent a regulatory constraint.
On the other hand the late receptor down-regulation
induced by TxA2 analogues, which according to present
data seems to occur in vivo too, could be relevant to the
antiaggregating treatment with drugs interfering with
TxA2 platelet receptors. In fact this platelet response
could potentiate the direct effect of the treatment.
The changes in the sensitivity of cells to an eicosanoid
has also been studied in humans in vivo during the
infusion of a PGI2 stable analogue (iloprost) (Sinzinger
etal., 1981). The functional desensitization after iloprost
infusion was found to be related to a reduction in the
number of PGI2 platelet receptors (Jaschonek et al.,
1988; Modesti et al., 1987) and to a decrease in the
amount of functional Gs (Edwards et al., 1987; Jaschonek
et al., 1988). The reduction of Gs also results in decreased
responsiveness to other antiaggregating agents such as
PGD2 or adenosine A2 which interact with Gs (Edwards
et al., 1987).
The mechanism underlying the receptor down-
regulation is still under investigation, even though
several hypotheses have been proposed such as internal-
ization, proteolysis or phosphorylation (Hollemberg,
1985). A recent paper by our group (Modesti et al.,
1990), showed the internalization of ONO11120 after its
binding to platelet specific TxA2 receptors, so suggesting
that the observed reduction may be due to the internaliz-
ation of the receptor molecule and its consequent removal
from the platelet surface.
In any case, the in vivo down regulation of TxA2
binding sites even after the stimulation with a TxA2
antagonist could represent an additional effect of the
treatment, potentially enhancing the antiplatelet effect
of TxA2 antagonists.
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